Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|September 4, 2024

Pharma Pulse 9/4/24: How Do You Change a Chatbot’s Mind? Understanding the Current State of M&A & more

The latest news for pharma industry insiders.

Understanding the Current State of M&A

After a post-pandemic slow down, the pharma industry saw a return of mergers and acquisitions (M&A) late last year and early this year. Cheryl Reicin, international chair of life sciences at Mintz, spoke with Pharmaceutical Executive about the current trends in the industry.

Cell and Gene Therapy: Becoming More Ordinary. Still Extraordinarily Expensive

Cell and gene therapies are becoming almost an everyday clinical reality. But the price tags? They still have shock value. Payers and providers are working out single-case agreements ahead of when the therapies are given.

How Do You Change a Chatbot’s Mind?

When I set out to improve my tainted reputation with chatbots, I discovered a new world of AI manipulation.

Rite Aid Corporation Names Matt Schroeder as Chief Executive Officer

Rite Aid Corporation (“Rite Aid” or the “Company”) announced that Matt Schroeder has been appointed Chief Executive Officer after the Company’s emergence from Chapter 11. Mr. Schroeder joined Rite Aid in 2000 and most recently served as the Company’s Chief Financial Officer. He succeeds Jeffrey S. Stein.

Cencora on LinkedIn

Despite the challenges the wholesale pharmaceutical community faces, we are well-prepared for the upcoming DSCSA deadline on November 27th.

VP of Manufacturer Operations and Data Services Gregg Gorniak detailed our proactive approach for enhancing our relationship with manufacturers and addressing drug shortages in a recent Pharmaceutical Commerce Magazine article: https://ow.ly/t8G650TeFyI

#DSCSADeadline #pharmasupplychain

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.